GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Talaris Therapeutics Inc (NAS:TALS) » Definitions » Volatility

Talaris Therapeutics (Talaris Therapeutics) Volatility : 96.94% (As of Jun. 12, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Talaris Therapeutics Volatility?

Volatility is a statistical measure of the dispersion of returns for a given security or market index, it shows how the price swings around its mean. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year. In most cases, the higher the volatility, the riskier the security.

As of today (2024-06-12), Talaris Therapeutics's Volatility is 96.94%.


Competitive Comparison of Talaris Therapeutics's Volatility

For the Biotechnology subindustry, Talaris Therapeutics's Volatility, along with its competitors' market caps and Volatility data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Talaris Therapeutics's Volatility Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Talaris Therapeutics's Volatility distribution charts can be found below:

* The bar in red indicates where Talaris Therapeutics's Volatility falls into.



Talaris Therapeutics  (NAS:TALS) Volatility Calculation

The annualized volatility is calculated as following:

σA=σM * 12
= 1/(n-1) ∑(Ri - R')^2 * 12

Where: σM is the monthly volatility, n is the number of months in the period, Ri is the security's historical monthly returns and R' is the arithmetic mean of monthly returns.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Talaris Therapeutics  (NAS:TALS) Volatility Explanation

Volatility is a statistical measure of the dispersion of returns for a given security or market index. It’s often measured as standard deviation or variance of historical returns over a certain period. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year.

Volatility reflects the uncertainty or risk of a security’s value. Generally speaking, a higher volatility suggests a higher risk, because it implies a wider fluctuation around average price. This means the price of the security can change dramatically in either direction within a short period. Conversely, a lower volatility means that the security's price is more steady, which suggests a lower risk.

Another measurement of relative volatility is Beta. Beta is a measure of systematic risk of a security or a portfolio in comparison to the market as a whole. Beta is usually compared to 1. A beta of greater than 1 indicates that the security's price will be more volatile than the market.


Talaris Therapeutics Volatility Related Terms

Thank you for viewing the detailed overview of Talaris Therapeutics's Volatility provided by GuruFocus.com. Please click on the following links to see related term pages.


Talaris Therapeutics (Talaris Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
93 Worcester Street, Wellesley, MA, USA, 02481
Talaris Therapeutics Inc is a late-clinical stage biotechnology company. It is developing transformative cell therapies with the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients as well as induce durable remissions in patients with severe autoimmune and immune-mediated disorders.
Executives
Cariad Chester director C/O TOURMALINE BIO, INC., 27 WEST 24TH STREET, SUITE 702, NEW YORK NY 10010
Yung H. Chyung officer: Chief Medical Officer C/O SCHOLAR ROCK, 620 MEMORIAL DR., 2ND FLOOR, CAMBRIDGE MA 02139
Caley Castelein director THOM. WEISEL HEALTHCARE VENTURES, ONE MONTGOMERY STREET, SAN FRANCISCO CA 94104
W Bradford Middlekauff officer: CBO, GC and Secretary 200 CONNELL DRIVE, SUITE 1600, BERKELEY HEIGHTS NJ 07922
Aaron Kantoff director C/O CENTESSA PHARMACEUTICALS PLC, D. HODGKIN BLDG, BABRAHAM RSRCH CAMPUS, CAMBRIDGE X0 CB22 3FH
Sandeep Chidambar Kulkarni director, officer: CEO 92 MORNINGSIDE AVE., APT 7E, NEW YORK NM 10027
Kevin Bruce Johnson officer: Chief Regulatory Officer C/O TOURMALINE BIO, INC., 27 WEST 24TH STREET, SUITE 702, NEW YORK NY 10010
Ryan F. Robinson officer: Interim CFO C/O TOURMALINE BIO, INC., 27 WEST 24TH STREET, SUITE 702, NEW YORK NY 10010
Parvinder Thiara director C/O TOURMALINE BIO, INC., 27 WEST 24TH STREET, SUITE 702, NEW YORK NY 10010
Susan Dana Jones officer: Chief Technology Officer C/O TOURMALINE BIO, INC., 27 WEST 24TH STREET, SUITE 702, NEW YORK NY 10010
Suzanne Ildstad director, 10 percent owner, officer: Chief Scientific Officer C/O TALARIS THERAPEUTICS, INC., 93 WORCESTER STREET, SUITE 120, WELLESLEY MA 02481
Scott Requadt director, officer: See Remarks 101 MAIN STREET, SUITE 1210, CAMBRIDGE MA 02142
Francois Nader director 550 HILLS DRIVE, BEDMINSTER NJ 07921
Karen L. Smith director C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Longitude Capital Partners Iii, Llc 10 percent owner 800 EL CAMINO, SUITE 220, MENLO PARK CA 94025

Talaris Therapeutics (Talaris Therapeutics) Headlines